drugset / Trial / NCT00476463
Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection
Phase 2
Completed
24 enrolled
The HIV Netherlands Australia Thailand Research Collaboration
Gilead Sciences · collabMinistry of Health, Thailand · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Combination therapy with anti-HBV activity may both increase HBV suppression rates and reduce emergence of resistant strains. Several new therapeutic agents are currently in development, however combination therapy trials in the HBV-infected population have only recently commenced. No such trials have been undertaken in the HIV/HBV co-infected population.
Timeline
- Start
- 2005-04
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | emtricitabine | Other / unclassified | 200 mg | — |